Scinovex
Subscribe
M

Michael T. Lotze

Novartis (Switzerland)ORCID https://orcid.org/0000-0003-3988-5419
h-index
—
Publications
—
Citations
—
i10-index
—
Impact (2-yr)
—

Top Publications

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Nature reviews. Immunology20052,484 citationsFirst authorCorresponding
The Beclin 1 network regulates autophagy and apoptosis
Cell Death and Differentiation20112,468 citations
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Journal of Clinical Oncology19992,025 citations
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
JNCI Journal of the National Cancer Institute20081,656 citations
<scp>PAMP</scp>s and <scp>DAMP</scp>s: signal 0s that spur autophagy and immunity
Immunological Reviews20121,161 citationsCorresponding
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
Annals of Surgery19891,007 citations
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity
Cell Reports2017920 citations
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Clinical Cancer Research2011893 citations
The grateful dead: damage‐associated molecular pattern molecules and reduction/oxidation regulate immunity
Immunological Reviews2007626 citationsFirst authorCorresponding
Classification of current anticancer immunotherapies
Oncotarget2014467 citations
Michael T. Lotze · Scinovex